Back Back
Cell No. : Cell Name
RCB2536 : T24  update : 2023/10/16
CommentHuman cell line derived from bladder cancer. Transitional cell carcinoma. TKG0443 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Fukuda, Hiroshi
Originator Bubenick, J.
Year of deposit 2007
Original cell TKG0443
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Female
Age at sampling 81 years
Tissue bladder
Disease name transitional-cell carcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0443)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_0554
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium MEM + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
deposit info
lot info
Reference information Reference 6
User's Publication 8

To topTop
190  Bubeník J, Kieler J, Tromholt V, Steven K, Indrová M, Toulcová A.  Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2  Folia Biol (Praha)  1986  32(3):183-94  PubMed ID: 3488923  
189  Bubeńik J, Kieler J, Perlmann P, Paulie S, Koho H, Christensen B, Dienstbier Z, Koprivová H, Pospísil J, Poucková P.  Monoclonal antibodies against human urinary bladder carcinomas: selectivity and utilization for gamma scintigraphy  Eur J Cancer Clin Oncol  1985  21(6):701-10  PubMed ID: 3894033   DOI: 10.1016/0277-5379(85)90267-6
191  Bubeník J, Kieler J, Perlmann P, Paulie S, Koho H, Christensen B, Dienstbier Z, Koprivová H, Pospísil J, Novák F.  Tumour localization of radiolabelled monoclonal antibody in mice bearing human urinary bladder (T24) carcinoma xenografts  Folia Biol (Praha)  1985  31(2):176-84  PubMed ID: 3894060  
4680  Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV.  Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.  Nature  1983  302:33-7  PubMed ID: 6298635   DOI: 10.1038/302033a0
1173  Bubeník J, Baresová M, Viklický V, Jakoubková J, Sainerová H, Donner J.  Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.  Int J Cancer  1973  11(3):765-73  PubMed ID: 4133950   DOI: 10.1002/ijc.2910110327
1172  Bubeník J, Perlmann P, Helmstein K, Moberger G.  Cellular and humoral immune responses to human urinary bladder carcinomas.  Int J Cancer  1970  5(3):310-9  PubMed ID: 5452065   DOI: 10.1002/ijc.2910050303

To topTop
User's Publication
21362  Ando K, Kurashina R, Motoi N, Iizuka T, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y.  Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.  Biochem Biophys Res Commun  2023  676:165-170  PubMed ID: 37517219   DOI: 10.1016/j.bbrc.2023.07.054
17640  Kobayashi T, Kishimoto S, Watanabe S, Yoshioka Y, Toyoda T, Ogawa K, Watanabe K, Totsuka Y, Wakabayashi K, Miyoshi N.  Cytotoxic Homo- and Hetero-Dimers of o-toluidine, o-anisidine, and Aniline Formed by In Vitro Metabolism  Chem Res Toxicol  2022  35(9):1625-1630  PubMed ID: 36001821   DOI: 10.1021/acs.chemrestox.2c00226
20774  Kubota Y, Fujioka Y, Patil A, Takagi Y, Matsubara D, Iijima M, Momose I, Naka R, Nakai K, Noda NN, Takekawa M.  Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.  Nat Commun  2022  13(1):4063  PubMed ID: 35831322   DOI: 10.1038/s41467-022-31690-w
16985  Kobayashi T, Toyoda T, Tajima Y, Kishimoto S, Tsunematsu Y, Sato M, Matsushita K, Yamada T, Shimamura Y, Masuda S, Ochiai M, Ogawa K, Watanabe K, Takamura-Enya T, Totsuka Y, Wakabayashi K, Miyoshi N.  o-Anisidine Dimer, 2-Methoxy- N4-(2-methoxyphenyl) Benzene-1,4-diamine, in Rat Urine Associated with Urinary bladder Carcinogenesis  Chem Res Toxicol  2021  34(3):912-919  PubMed ID: 33587850   DOI: 10.1021/acs.chemrestox.0c00536
13009  Tajima Y, Toyoda T, Hirayama Y, Matsushita K, Yamada T, Ogawa K, Watanabe K, Takamura-Enya T, Totsuka Y, Wakabayashi K, Miyoshi N.  Novel o-Toluidine Metabolite in Rat Urine Associated with Urinary Bladder Carcinogenesis.  Chem Res Toxicol  2020    PubMed ID: 32343562   DOI: 10.1021/acs.chemrestox.0c00098
13311  Sugiyama T, Ozono S, Miyake H.  Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma.  Anticancer Res  2020    PubMed ID: 33109571   DOI: 10.21873/anticanres.14654
13329  Matsumura E, Kosuge N, Nakanishi S, Suda T, Sugawa A, Fujimura T, Miyagi R, Yoshimi N, Saito S.  Urine Lactoferrin as a Potential Biomarker Reflecting the Degree of Malignancy in Urothelial Carcinoma of the Bladder.  Tohoku J Exp Med  2020    PubMed ID: 33162487   DOI: 10.1620/tjem.252.225
14268  Yamashita T, Higashi M, Momose S, Morozumi M, Tamaru JI.  Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer  Int J Oncol  2017  51(2):579-586  PubMed ID: 28714514   DOI: 10.3892/ijo.2017.4031

Back Back Return Top Page